Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).
Meynard JL, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S, Spire B, Todesco E, Bouchaud O, Fagard C, Chene G, Girard PM; ANRS 140 DREAM Study Group. Meynard JL, et al. Among authors: fagard c. J Antimicrob Chemother. 2018 Jun 1;73(6):1672-1676. doi: 10.1093/jac/dky055. J Antimicrob Chemother. 2018. PMID: 29584910 Clinical Trial.
Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).
Piroth L, Moinot L, Yeni P, Avettand-Fénoel V, Reynes J, Girard PM, Marchou B, Georget A, Rouzioux C, Autran B, Duvillard L, Chêne G, Fagard C; ANRS 141 TIPI Trial Study Group. Piroth L, et al. Among authors: fagard c. J Antimicrob Chemother. 2016 Feb;71(2):490-6. doi: 10.1093/jac/dkv369. Epub 2015 Nov 14. J Antimicrob Chemother. 2016. PMID: 26568566 Clinical Trial.
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group. Lortholary O, et al. Among authors: fagard c. J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17. J Antimicrob Chemother. 2016. PMID: 26679250
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group. Joly V, et al. Among authors: fagard c. Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19. Antimicrob Agents Chemother. 2013. PMID: 23165467 Free PMC article. Clinical Trial.
Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.
Gantner P, Morand-Joubert L, Sueur C, Raffi F, Fagard C, Lascoux-Combe C, Salmon D, Amiel C, Lambert-Niclot S, Fofana DB, Viard JP, Fafi-Kremer S, Rouzioux C, Avettand-Fenoel V, Ghosn J. Gantner P, et al. Among authors: fagard c. J Antimicrob Chemother. 2016 Mar;71(3):751-61. doi: 10.1093/jac/dkv395. Epub 2015 Dec 16. J Antimicrob Chemother. 2016. PMID: 26676973
Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course.
Raffi F, Le Moing V, Assuied A, Habak S, Spire B, Cazanave C, Billaud E, Dellamonica P, Ferry T, Fagard C, Leport C; ANRS CO8 COPILOTE Study Group. Raffi F, et al. Among authors: fagard c. J Antimicrob Chemother. 2017 Jan;72(1):240-245. doi: 10.1093/jac/dkw369. Epub 2016 Sep 13. J Antimicrob Chemother. 2017. PMID: 27629069
Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.
Mercié P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Bénard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chêne G; ANRS 144 Inter-ACTIV study group. Mercié P, et al. Among authors: fagard c. Lancet HIV. 2018 Mar;5(3):e126-e135. doi: 10.1016/S2352-3018(18)30002-X. Epub 2018 Jan 9. Lancet HIV. 2018. PMID: 29329763 Clinical Trial.
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort. Wittkop L, et al. Among authors: fagard c. J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31. J Antimicrob Chemother. 2009. PMID: 19336453 Free PMC article. Clinical Trial.
Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE).
Avettand-Fenoel V, Bouteloup V, Mélard A, Fagard C, Chaix ML, Leclercq P, Chêne G, Viard JP, Rouzioux C; members of the ETOILE study. Avettand-Fenoel V, et al. Among authors: fagard c. J Antimicrob Chemother. 2010 Oct;65(10):2212-4. doi: 10.1093/jac/dkq282. Epub 2010 Jul 28. J Antimicrob Chemother. 2010. PMID: 20667886
46 results